NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $290,891 | +3.1% | 488,400 | -0.4% | 0.00% | – |
| Q2 2023 | $282,078 | -59.6% | 490,400 | -50.7% | 0.00% | – |
| Q1 2023 | $698,942 | -65.3% | 994,370 | +11.4% | 0.00% | -100.0% |
| Q4 2022 | $2,017,000 | -20.6% | 892,949 | +12.5% | 0.00% | 0.0% |
| Q3 2022 | $2,541,000 | -12.6% | 794,019 | +3.8% | 0.00% | 0.0% |
| Q2 2022 | $2,907,000 | -30.9% | 764,921 | -2.0% | 0.00% | 0.0% |
| Q1 2022 | $4,208,000 | -61.0% | 780,910 | -2.3% | 0.00% | -66.7% |
| Q4 2021 | $10,803,000 | +118.7% | 799,698 | +190.7% | 0.00% | +50.0% |
| Q3 2021 | $4,940,000 | -0.4% | 275,101 | -4.8% | 0.00% | 0.0% |
| Q2 2021 | $4,959,000 | -87.4% | 288,975 | -85.3% | 0.00% | -84.6% |
| Q1 2021 | $39,325,000 | +649.5% | 1,966,238 | +537.0% | 0.01% | +550.0% |
| Q4 2020 | $5,247,000 | -3.3% | 308,660 | -5.6% | 0.00% | 0.0% |
| Q3 2020 | $5,427,000 | -32.5% | 327,100 | -5.8% | 0.00% | -33.3% |
| Q2 2020 | $8,043,000 | +27.5% | 347,268 | -1.8% | 0.00% | 0.0% |
| Q1 2020 | $6,310,000 | -23.5% | 353,563 | -7.4% | 0.00% | 0.0% |
| Q4 2019 | $8,245,000 | +527.0% | 381,984 | +429.7% | 0.00% | +200.0% |
| Q3 2019 | $1,315,000 | -36.6% | 72,120 | +23.8% | 0.00% | 0.0% |
| Q2 2019 | $2,073,000 | -24.0% | 58,272 | -28.3% | 0.00% | 0.0% |
| Q1 2019 | $2,728,000 | +17.8% | 81,237 | +15.3% | 0.00% | 0.0% |
| Q4 2018 | $2,315,000 | -55.4% | 70,435 | -17.3% | 0.00% | -50.0% |
| Q3 2018 | $5,193,000 | +42.0% | 85,188 | +11.7% | 0.00% | 0.0% |
| Q2 2018 | $3,656,000 | -71.1% | 76,244 | -35.8% | 0.00% | -66.7% |
| Q1 2018 | $12,631,000 | -76.5% | 118,850 | -86.8% | 0.01% | -75.0% |
| Q4 2017 | $53,657,000 | +136.6% | 898,466 | -4.9% | 0.02% | +118.2% |
| Q3 2017 | $22,677,000 | +21.8% | 944,883 | -0.8% | 0.01% | +22.2% |
| Q2 2017 | $18,620,000 | -9.1% | 952,443 | +9.1% | 0.01% | -18.2% |
| Q1 2017 | $20,489,000 | +117.6% | 872,933 | +13.7% | 0.01% | +120.0% |
| Q4 2016 | $9,418,000 | -19.4% | 767,542 | +12.8% | 0.01% | -28.6% |
| Q3 2016 | $11,690,000 | +24.7% | 680,487 | +3.3% | 0.01% | +40.0% |
| Q2 2016 | $9,376,000 | +7.6% | 658,966 | +4.0% | 0.01% | 0.0% |
| Q1 2016 | $8,711,000 | -16.1% | 633,533 | +2.8% | 0.01% | -16.7% |
| Q4 2015 | $10,382,000 | +52.2% | 616,119 | -1.0% | 0.01% | +50.0% |
| Q3 2015 | $6,822,000 | -11.9% | 622,439 | +0.6% | 0.00% | 0.0% |
| Q2 2015 | $7,744,000 | +1205.9% | 618,935 | +1047.2% | 0.00% | – |
| Q1 2015 | $593,000 | +49.4% | 53,951 | +110.7% | 0.00% | – |
| Q4 2014 | $397,000 | +264.2% | 25,603 | +185.2% | 0.00% | – |
| Q3 2014 | $109,000 | -44.1% | 8,976 | -41.2% | 0.00% | – |
| Q2 2014 | $195,000 | +572.4% | 15,257 | +550.1% | 0.00% | – |
| Q1 2014 | $29,000 | +26.1% | 2,347 | +14.7% | 0.00% | – |
| Q4 2013 | $23,000 | -76.5% | 2,047 | -78.3% | 0.00% | – |
| Q3 2013 | $98,000 | -10.1% | 9,446 | 0.0% | 0.00% | – |
| Q2 2013 | $109,000 | – | 9,446 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |